Inflammatory Bowel Diseases

Skip Navigation LinksHome > January 2012 - Volume 18 - Issue 1 > Stopping immunomodulators and biologics in inflammatory bowe...
Inflammatory Bowel Diseases:
doi: 10.1002/ibd.21792
Clinical Reviews

Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission

Clarke, Kofi MD1; Regueiro, Miguel MD1,*

Collapse Box


Abstract:: The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop therapy is yet unresolved. Recently, the term very deep remission (defined as clinical remission [CDAI < 150] and endoscopic remission) has been applied to patients on immunomodulators/biologics who have no clinical symptoms or objective signs of inflammatory disease. Whether or not patients who achieve and maintain a very deep remission may successfully stop treatment is not known. This article will review the current data on stopping treatment in IBD and identify certain factors that are associated with a high relapse rate after discontinuing treatment. Where evidence‐based data are lacking, the authors provide their opinion. (Inflamm Bowel Dis 2011;)

© Crohn's & Colitis Foundation of America, Inc.

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.